Breaking Finance News

A report released today by Cantor Fitzgerald about Amarin (NASDAQ:AMRN) bumps the target price to $6.00

Cantor Fitzgerald bumped up the target of Amarin (NASDAQ:AMRN) to $6.00 stating a potential upside of 0.88%.

Boasting a price of $3.20, Amarin (NASDAQ:AMRN) traded 0.00% even on the day. With the last stock price close up 39.70% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Amarin has recorded a 50-day average of $2.99 and a two hundred day average of $2.29. Volume of trade was down over the average, with 1,558,567 shares of AMRN changing hands under the typical 3,861,300

Performance Chart


With a total market value of $0, Amarin has with a 52 week low of $1.24 and a 52 week high of $3.46 .

In addition to Cantor Fitzgerald reporting its stock price target, a total of 2 brokers have issued a report on the company. The average stock price target is $8.00 with 1 broker rating the stock a strong buy, 2 brokers rating the stock a buy, 1 broker rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About Amarin (NASDAQ:AMRN)

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company's lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. The Company operates in the business segment of development and commercialization of Vascepa. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its Distributors, that in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers. The Company markets Vascepa in the United States.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.